Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease. / Adrian, Therese; Hornum, Mads; Knop, Filip Krag; Almdal, Thomas; Rossing, Peter; Lida, Lisa; Heinrich, Niels S.; Boer, Vincent Oltman; Marsman, Anouk; Petersen, Esben Thade; Siebner, Hartwig Roman; Feldt-Rasmussen, Bo.
In: Nephron, Vol. 147, No. 6, 2023, p. 317–328.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes and Chronic Kidney Disease
AU - Adrian, Therese
AU - Hornum, Mads
AU - Knop, Filip Krag
AU - Almdal, Thomas
AU - Rossing, Peter
AU - Lida, Lisa
AU - Heinrich, Niels S.
AU - Boer, Vincent Oltman
AU - Marsman, Anouk
AU - Petersen, Esben Thade
AU - Siebner, Hartwig Roman
AU - Feldt-Rasmussen, Bo
PY - 2023
Y1 - 2023
N2 - Background: Nonalcoholic fatty liver disease (NAFLD) is suggested as a risk factor for chronic kidney disease (CKD). The incidence of NAFLD is rising globally in parallel to the increasing incidences of obesity and type 2 diabetes. Diabetes remains the leading cause of CKD, but the co-existence of NAFLD, CKD, and type 2 diabetes is not well elucidated. Here, we evaluated the prevalence of NAFLD in patients with type 2 diabetes with and without CKD. Methods: This was a cross-sectional study including 50 patients with type 2 diabetes and CKD stages 3-5 (no dialysis), and 50 patients with type 2 diabetes without CKD. Liver fat content was estimated by proton magnetic resonance spectroscopy and magnetic resonance imaging proton density fat fraction. NAFLD was defined as liver fat fraction >= 5.6% according to guidelines. Results: Mean age was 72 +/- 4.9 years in patients with CKD and 65.9 +/- 7.8 years in patients without CKD (p < 0.0001). Three out of four participants were men. BMI was 28.6 +/- 3.5 kg/m(2) and 27 +/- 4.0 kg/m(2) in patients with and without CKD, respectively (p = 0.0087). NAFLD was identified in 22 (44%) patients with CKD and 19 (38%) patients without CKD (p = 0.6845). Median (IQR) liver fat fraction was 4.7% (3.0-8.5) and 4.1% (2.9-7.7) in patients with and without CKD, respectively (difference in geometric means 5.3%, 95% CI -23; 45, p = 0.7463). Conclusion: These findings do not support any association between NAFLD and CKD (stages 3-5) in patients with type 2 diabetes.
AB - Background: Nonalcoholic fatty liver disease (NAFLD) is suggested as a risk factor for chronic kidney disease (CKD). The incidence of NAFLD is rising globally in parallel to the increasing incidences of obesity and type 2 diabetes. Diabetes remains the leading cause of CKD, but the co-existence of NAFLD, CKD, and type 2 diabetes is not well elucidated. Here, we evaluated the prevalence of NAFLD in patients with type 2 diabetes with and without CKD. Methods: This was a cross-sectional study including 50 patients with type 2 diabetes and CKD stages 3-5 (no dialysis), and 50 patients with type 2 diabetes without CKD. Liver fat content was estimated by proton magnetic resonance spectroscopy and magnetic resonance imaging proton density fat fraction. NAFLD was defined as liver fat fraction >= 5.6% according to guidelines. Results: Mean age was 72 +/- 4.9 years in patients with CKD and 65.9 +/- 7.8 years in patients without CKD (p < 0.0001). Three out of four participants were men. BMI was 28.6 +/- 3.5 kg/m(2) and 27 +/- 4.0 kg/m(2) in patients with and without CKD, respectively (p = 0.0087). NAFLD was identified in 22 (44%) patients with CKD and 19 (38%) patients without CKD (p = 0.6845). Median (IQR) liver fat fraction was 4.7% (3.0-8.5) and 4.1% (2.9-7.7) in patients with and without CKD, respectively (difference in geometric means 5.3%, 95% CI -23; 45, p = 0.7463). Conclusion: These findings do not support any association between NAFLD and CKD (stages 3-5) in patients with type 2 diabetes.
KW - Chronic kidney disease
KW - Magnetic resonance imaging
KW - Nonalcoholic fatty liver disease
KW - Prevalence
KW - Type 2 diabetes
KW - GAMMA-GLUTAMYL-TRANSFERASE
KW - HEPATIC STEATOSIS
KW - PREVALENCE
KW - RISK
KW - ASSOCIATION
KW - MELLITUS
KW - EPIDEMIOLOGY
KW - FIBROSIS
U2 - 10.1159/000528080
DO - 10.1159/000528080
M3 - Journal article
C2 - 36630927
VL - 147
SP - 317
EP - 328
JO - Nephron - Clinical Practice
JF - Nephron - Clinical Practice
SN - 1660-8151
IS - 6
ER -
ID: 335674249